Core Viewpoint - Capri Holdings has raised its annual revenue forecast due to consistent demand for apparel and handbags from its brands, Jimmy Choo and Michael Kors [1] Group 1: Company Performance - Capri Holdings is experiencing steady demand for its products, which has led to an optimistic outlook for revenue [1] Group 2: Brand Insights - The brands Jimmy Choo and Michael Kors are specifically highlighted as key contributors to the company's revenue growth [1]

Group 1 - Eni and Q8 Italy have reached an agreement to jointly construct and operate a new biorefinery in Priolo, Sicily [1] - This initiative represents a significant advancement in the transformation of the former chemical facilities at the site [1]

HP Inc on Tuesday named Bruce Broussard as the company's interim chief executive officer effective immediately. ...

PayPal said on Tuesday it has named Enrique Lores as president and CEO, effective March 1. ...

Core Viewpoint - PayPal's profit forecast for 2026 is considered lackluster, and the company reported fourth-quarter earnings that fell below Wall Street expectations, influenced by weaker U.S. retail spending and slower growth in its business [1] Financial Performance - The fourth-quarter earnings reported by PayPal were below Wall Street expectations, indicating potential challenges in meeting future financial targets [1] - The company is facing pressure from a decline in U.S. retail spending, which may impact its revenue growth [1] Growth Outlook - The profit forecast for 2026 is viewed as disappointing, suggesting that the company may struggle to achieve significant growth in the coming years [1] - Slower growth in PayPal's business is a concern, reflecting broader economic trends that could affect its performance [1]

Core Insights - Pfizer reported fourth-quarter profit exceeding Wall Street estimates, driven by sustained demand for older drugs like blood thinner Eliquis, which helped mitigate declining sales from COVID-related products [1] Financial Performance - The company’s fourth-quarter profit was above expectations, indicating strong performance in its traditional drug portfolio despite challenges in the COVID product segment [1]

Core Insights - Pfizer's experimental obesity drug demonstrated a weight loss of up to 12.3% in patients without diabetes during a mid-stage trial [1] Company Summary - The obesity drug was acquired through the Metsera deal, indicating Pfizer's strategic expansion into the obesity treatment market [1]

What matters in U.S. and global markets today ...

Core Viewpoint - Marathon Petroleum exceeded Wall Street's profit expectations for the fourth quarter, driven by robust refining margins [1] Group 1: Financial Performance - The company reported a significant increase in profits, attributed to strong refining margins [1] - The fourth-quarter results surpassed analysts' forecasts, indicating a positive trend in financial performance [1] Group 2: Industry Context - The refining sector is experiencing favorable conditions, contributing to improved margins for companies like Marathon Petroleum [1] - Strong demand for refined products has bolstered the overall profitability of the refining industry [1]

Core Viewpoint - Merck & Co has projected 2026 sales and profits to be below Wall Street estimates due to the anticipated impact of losing patent exclusivity on its diabetes drug Januvia and other medications, which is expected to be more significant than analysts had previously estimated [1] Group 1 - The loss of patent exclusivity on Januvia is a major factor contributing to the forecasted decline in sales and profits [1] - Analysts had previously underestimated the impact of patent expirations on Merck's financial performance [1] - The company is facing challenges from increased competition in the diabetes medication market following the expiration of patents [1]